Understanding medical mistrust and HPV vaccine hesitancy among multiethnic parents in Los Angeles J Behav Med. 2023 04; 46(1-2):100-115. . View in PubMed

Diversity of Anal HPV and Non-HPV Sexually Transmitted Infections and Concordance with Genital Infections in HIV-Infected and HIV-Uninfected Women in the Tapajós Region, Amazon, Brazil Viruses. 2023 06 06; 15(6). . View in PubMed

Examining multilevel influences on parental HPV vaccine hesitancy among multiethnic communities in Los Angeles: a qualitative analysis BMC Public Health. 2023 03 22; 23(1):545. . View in PubMed

Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic Vaccine Targeting Human Papillomavirus Cancers (Basel). 2022 Sep 05; 14(17). . View in PubMed

Single-cell genomics identifies immune response to neoadjuvant chemoradiotherapy EBioMedicine. 2022 12; 86:104389. . View in PubMed

Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials Cancer Treat Rev. 2022 05; 106:102385. . View in PubMed

Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors Cancer Immunol Res. 2020 07; 8(7):856-868. . View in PubMed

The Essential Role of anxA2 in Langerhans Cell Birbeck Granules Formation Cells. 2020 04 15; 9(4). . View in PubMed

Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929) Clin Cancer Res. 2020 11 01; 26(21):5621-5630. . View in PubMed

Theta-Defensins Inhibit High-Risk Human Papillomavirus Infection Through Charge-Driven Capsid Clustering Front Immunol. 2020; 11:561843. . View in PubMed

Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy Oncoimmunology. 2020 11 29; 9(1):1851539. . View in PubMed

TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy Front Immunol. 2020; 11:922. . View in PubMed

Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease Vaccine. 2019 05 16; 37(22):2915-2924. . View in PubMed

Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study BMC Cancer. 2018 Oct 11; 18(1):970. . View in PubMed

Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors Gynecol Oncol. 2018 10; 151(1):102-110. . View in PubMed

Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses Cancer Immunol Res. 2018 07; 6(7):870-880. . View in PubMed

Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation Sci Rep. 2018 08 03; 8(1):11642. . View in PubMed

Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response PLoS One. 2018; 13(1):e0191311. . View in PubMed

Annexin A2 in Virus Infection Front Microbiol. 2018; 9:2954. . View in PubMed

Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy Oncotarget. 2017 Sep 26; 8(43):74378-74390. . View in PubMed

Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions Papillomavirus Res. 2017 12; 4:90-98. . View in PubMed

A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression Front Immunol. 2017; 8:563. . View in PubMed

The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis J Virol. 2016 Dec 01; 90(23):10629-10641. . View in PubMed

Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection J Gen Virol. 2016 Feb; 97(2):422-434. . View in PubMed

T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation Papillomavirus Res. 2016 12; 2:21-30. . View in PubMed

Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment AIDS Patient Care STDS. 2016 07; 30(7):291-306. . View in PubMed

Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells J Interferon Cytokine Res. 2016 05; 36(5):291-301. . View in PubMed

Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4 J Neuroimmunol. 2016 10 15; 299:70-78. . View in PubMed

Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro Virol J. 2016 11 18; 13(1):187. . View in PubMed

Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients J Acquir Immune Defic Syndr. 2016 09 01; 73(1):27-33. . View in PubMed

Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases Hum Vaccin Immunother. 2016 06 02; 12(6):1418-29. . View in PubMed

Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C Clin Immunol. 2015 Dec; 161(2):197-208. . View in PubMed

Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C Papillomavirus Res. 2015 Dec 01; 1:12-21. . View in PubMed

A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours J Gen Virol. 2015 Sep; 96(9):2764-2768. . View in PubMed

Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes Prostate. 2015 Feb 15; 75(3):280-91. . View in PubMed

Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro Methods Mol Biol. 2015; 1249:135-49. . View in PubMed

Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection J Antimicrob Chemother. 2015; 70(6):1686-90. . View in PubMed

Functional analysis of HPV-like particle-activated Langerhans cells in vitro Methods Mol Biol. 2015; 1249:333-50. . View in PubMed

Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression J Immunol. 2014 May 15; 192(10):4748-57. . View in PubMed

Suppression of Langerhans cell activation is conserved amongst human papillomavirus a and ß genotypes, but not a µ genotype Virology. 2014 Mar; 452-453:279-86. . View in PubMed

The evolving field of human papillomavirus receptor research: a review of binding and entry J Virol. 2013 Jun; 87(11):6062-72. . View in PubMed

Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor Oncol Rep. 2013 May; 29(5):1962-8. . View in PubMed

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies J Transl Med. 2012 Nov 05; 10:218. . View in PubMed

Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability Int Rev Immunol. 2012 Oct; 31(5):302-20. . View in PubMed

Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia J Pathol. 2012 Apr; 226(5):713-22. . View in PubMed

Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma Int Rev Immunol. 2012 Feb; 31(1):22-42. . View in PubMed

Perspective for prophylaxis and treatment of cervical cancer: an immunological approach Int Rev Immunol. 2012 Feb; 31(1):3-21. . View in PubMed

In this issue: targeting Human Papilloma Virus-associated disease, from cervical to head and neck carcinoma…and more Int Rev Immunol. 2012 Feb; 31(1):1-2. . View in PubMed

The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection PLoS One. 2012; 7(8):e43519. . View in PubMed

Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer Prostate. 2012 Jan; 72(1):12-23. . View in PubMed

Notch-ing from T-cell to B-cell lymphoid malignancies Cancer Lett. 2011 Sep 01; 308(1):1-13. . View in PubMed

Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy J Immunother. 2011 Jul-Aug; 34(6):490-9. . View in PubMed

The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma Int J Oncol. 2011 Jul; 39(1):185-91. . View in PubMed

Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer Int Rev Immunol. 2011 Apr-Jun; 30(2-3):127-37. . View in PubMed

Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies Int Rev Immunol. 2011 Apr-Jun; 30(2-3):71-86. . View in PubMed

Bovine papillomavirus DNA can be detected in keratinocytes of equine sarcoid tumors Vet Microbiol. 2010 Dec 15; 146(3-4):269-75. . View in PubMed

Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting Mol Interv. 2010 Aug; 10(4):197-203. . View in PubMed

Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression Cancer Res. 2010 May 15; 70(10):3955-64. . View in PubMed

Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer PLoS One. 2010 May 12; 5(5):e10471. . View in PubMed

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508 Cancer. 2010 Jan 15; 116(2):424-31. . View in PubMed

Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages Vaccine. 2009 Dec 30; 27 Suppl 6:G52-9. . View in PubMed

A major role for the minor capsid protein of human papillomavirus type 16 in immune escape J Immunol. 2009 Nov 15; 183(10):6151-6. . View in PubMed

Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, DC. Head Neck. 2009 Nov; 31(11):1393-422. . View in PubMed

Immunogenicity of an HPV-16 L2 DNA vaccine Vaccine. 2009 Oct 30; 27(46):6432-4. . View in PubMed

Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors Clin Cancer Res. 2009 Oct 01; 15(19):6167-76. . View in PubMed

Sperm protein 17 is expressed in the sperm fibrous sheath J Transl Med. 2009 Jul 15; 7:61. . View in PubMed

Prostate stem cell antigen: a prospective therapeutic and diagnostic target Cancer Lett. 2009 May 18; 277(2):126-32. . View in PubMed

Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition Cancer Immunol Immunother. 2009 May; 58(5):719-28. . View in PubMed

Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer Gynecol Oncol. 2009 May; 113(2):256-63. . View in PubMed

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization Prostate. 2009 May 01; 69(6):571-84. . View in PubMed

Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16 J Immunol. 2009 Mar 01; 182(5):2919-28. . View in PubMed

rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer Viral Immunol. 2008 Dec; 21(4):435-42. . View in PubMed

Peptide-based vaccines for cancer: realizing their potential Expert Rev Vaccines. 2008 Dec; 7(10):1533-45. . View in PubMed

Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells J Transl Med. 2008 Oct 05; 6:56. . View in PubMed

Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells Oncogene. 2008 Oct 02; 27(44):5833-44. . View in PubMed

Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer J Immunother. 2008 Oct; 31(8):693-703. . View in PubMed

Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells Cancer Immunol Immunother. 2008 Jun; 57(6):789-97. . View in PubMed

Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines Cancer Immun. 2008 Apr 24; 8:8. . View in PubMed

A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting Immunol Rev. 2008 Apr; 222:316-27. . View in PubMed

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) Cancer Immunol Immunother. 2008 Mar; 57(3):303-15. . View in PubMed

AKAP-4: a novel cancer testis antigen for multiple myeloma Br J Haematol. 2008 Feb; 140(4):465-8. . View in PubMed

Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity Cancer Res. 2008 Feb 01; 68(3):861-9. . View in PubMed

Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions Int J Cancer. 2008 Jan 15; 122(2):247-59. . View in PubMed

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs Int Immunol. 2007 Oct; 19(10):1223-34. . View in PubMed

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia Gynecol Oncol. 2007 Sep; 106(3):558-66. . View in PubMed

Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity J Immunol. 2007 Jun 15; 178(12):7587-97. . View in PubMed

Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides J Transl Med. 2007 Jun 07; 5:26. . View in PubMed

Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials Int Rev Immunol. 2007 May-Aug; 26(3-4):197-222. . View in PubMed

The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors Vaccine. 2007 Apr 30; 25(17):3437-44. . View in PubMed

Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax J Transl Med. 2007 Apr 23; 5:20. . View in PubMed

Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7 Clin Cancer Res. 2007 Apr 15; 13(8):2385-91. . View in PubMed

A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17 J Immunol Methods. 2007 Apr 10; 321(1-2):86-93. . View in PubMed

Mechanisms used by human papillomaviruses to escape the host immune response Curr Cancer Drug Targets. 2007 Feb; 7(1):79-89. . View in PubMed

In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer Cancer Res. 2007 Feb 01; 67(3):1344-51. . View in PubMed

Therapeutic vaccination for HPV induced cervical cancers Dis Markers. 2007; 23(4):337-52. . View in PubMed

Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant J Transl Med. 2006 Oct 23; 4:42. . View in PubMed

T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells Cancer Immunol Immunother. 2006 Sep; 55(9):1142-50. . View in PubMed

Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion Vaccine. 2006 Jun 12; 24(24):5235-44. . View in PubMed

Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors In Vitro Cell Dev Biol Anim. 2006 Mar-Apr; 42(3-4):89-95. . View in PubMed

Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma Hum Pathol. 2005 Dec; 36(12):1289-93. . View in PubMed

Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro Hum Immunol. 2005 Jul; 66(7):762-72. . View in PubMed

Vaccination Against Cervical Cancer: Hopes and Realities Am J Cancer (Auckl). 2005 Jul; 4(4):207-219. . View in PubMed

Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation J Immunol. 2005 Jun 01; 174(11):7172-8. . View in PubMed

Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells Vaccine. 2005 Feb 25; 23(14):1720-9. . View in PubMed

Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor Cancer Res. 2005 Feb 15; 65(4):1570-6. . View in PubMed

The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management Eur J Gynaecol Oncol. 2005; 26(2):129-42. . View in PubMed

Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy J Transl Med. 2004 Jun 22; 2(1):20. . View in PubMed

Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes Clin Cancer Res. 2004 May 15; 10(10):3301-8. . View in PubMed

Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors Oncogene. 2004 May 13; 23(22):3972-9. . View in PubMed

Sperm protein 17 is expressed in human somatic ciliated epithelia J Histochem Cytochem. 2004 Apr; 52(4):549-54. . View in PubMed

Peptide-based vaccines for cancer immunotherapy Expert Opin Biol Ther. 2004 Feb; 4(2):181-98. . View in PubMed

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes Vaccine. 2004 Jan 02; 22(3-4):520-7. . View in PubMed

Cure of glioma: a space not yet occupied for the lesion Cancer Invest. 2004; 22(3):479-80. . View in PubMed

Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo Blood. 2004 Jan 01; 103(1):177-84. . View in PubMed

Cancer immunotherapy: avoiding the road to perdition J Transl Med. 2004 07 29; 2(1):26. . View in PubMed

Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes Cancer Invest. 2004; 22(3):417-34. . View in PubMed

Synopsis of the 5th annual Cancer Vaccines and Immunotherapy Colloquium at Walker's Cay Cancer Immunol Immunother. 2003 Oct; 52(10):655-60. . View in PubMed

Is sperm protein 17 a useful target for tumor immunotherapy? Blood. 2003 Sep 15; 102(6):2308-9.. View in PubMed

Advances in prophylactic cancer vaccine research Expert Rev Anticancer Ther. 2003 Aug; 3(4):537-45. . View in PubMed

Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines Vaccine. 2003 Jul 04; 21(23):3219-27. . View in PubMed

Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells Cancer Res. 2003 Jul 01; 63(13):3478-82. . View in PubMed

Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation Vaccine. 2003 Jun 02; 21(19-20):2506-15. . View in PubMed

Recent progress in tumour vaccine development Expert Opin Investig Drugs. 2003 Jun; 12(6):971-81. . View in PubMed

HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation J Cell Physiol. 2003 Mar; 194(3):356-62. . View in PubMed

CD4+ T cell matters in tumor immunity Int Rev Immunol. 2003 Mar-Apr; 22(2):113-40. . View in PubMed

Advances in immunotherapy for prostate cancer Adv Cancer Res. 2003; 87:159-94. . View in PubMed

Cervical cancer vaccines: recent advances in HPV research Viral Immunol. 2003; 16(2):111-21. . View in PubMed

HPV protein/peptide vaccines: from animal models to clinical trials Front Biosci. 2003 Jan 01; 8:s81-91. . View in PubMed

Synopsis of the 4th Walker's Cay Meeting on Cancer Vaccines, 7-10 March 2002 Cancer Immunol Immunother. 2002 Dec; 51(11-12):674-6. . View in PubMed

Emerging strategies in tumor vaccines Curr Opin Oncol. 2002 Nov; 14(6):641-8. . View in PubMed

Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice Cancer Res. 2002 Oct 15; 62(20):5792-9. . View in PubMed

The Notch ligand Jagged-1 is able to induce maturation of monocyte-derived human dendritic cells J Immunol. 2002 Oct 15; 169(8):4273-8. . View in PubMed

Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses J Immunol. 2002 Sep 15; 169(6):3242-9. . View in PubMed

Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells Nat Med. 2002 Sep; 8(9):979-86. . View in PubMed

Ins and outs of clinical trials with peptide-based vaccines Front Biosci. 2002 May 01; 7:e204-13. . View in PubMed

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy J Immunother. 2002 Mar-Apr; 25(2):97-138. . View in PubMed

Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells Am J Pathol. 2002 Feb; 160(2):521-8. . View in PubMed

Immunodominance and tumor escape Semin Cancer Biol. 2002 Feb; 12(1):25-31. . View in PubMed

The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy Adv Cancer Res. 2002; 86:113-48. . View in PubMed

Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention Intervirology. 2002; 45(4-6):300-7. . View in PubMed

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer Proc Natl Acad Sci U S A. 2001 Dec 04; 98(25):14565-70. . View in PubMed

Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines Virology. 2001 Nov 25; 290(2):350-60. . View in PubMed

Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA Cancer Res. 2001 Nov 01; 61(21):7861-7. . View in PubMed

Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice Cancer Res. 2001 Aug 01; 61(15):5857-60. . View in PubMed

Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo Cancer Res. 2001 Jul 15; 61(14):5499-504. . View in PubMed

Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide J Immunol. 2001 Jun 15; 166(12):7151-7. . View in PubMed

Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro J Immunol. 2001 May 15; 166(10):5917-24. . View in PubMed

Prospect for immunotherapy of acute lymphoblastic leukemia Leukemia. 2001 May; 15(5):701-6. . View in PubMed

Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine J Immunol. 2001 May 01; 166(9):5366-73. . View in PubMed

Physical interaction of human papillomavirus virus-like particles with immune cells Int Immunol. 2001 May; 13(5):633-41. . View in PubMed

Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells J Immunol. 2001 May 01; 166(9):5398-406. . View in PubMed

Human T cell responses to endogenously presented HLA-A*0201 restricted peptides of Simian virus 40 large T antigen J Cell Biochem. 2001 Apr 2-27; 82(1):155-62. . View in PubMed

Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7 Clin Cancer Res. 2001 Mar; 7(3 Suppl):788s-795s. . View in PubMed

A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy Clin Cancer Res. 2001 Mar; 7(3 Suppl):876s-881s. . View in PubMed

Tracking the common ancestry of antigenically distinct cancer variants Clin Cancer Res. 2001 Mar; 7(3 Suppl):871s-875s. . View in PubMed

Cervical cancer vaccines: emerging concepts and developments J Cell Physiol. 2001 Feb; 186(2):169-82. . View in PubMed

Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice Virology. 2001 Jan 05; 279(1):354-60. . View in PubMed

A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive Clin Cancer Res. 2000 Sep; 6(9):3406-16. . View in PubMed

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma J Immunother. 2000 Mar-Apr; 23(2):255-66. . View in PubMed

Notch signaling as a target in multimodality cancer therapy Curr Opin Mol Ther. 2000 Feb; 2(1):55-65. . View in PubMed

Successful immunotherapy of an intraocular tumor in mice Cancer Res. 1999 Oct 15; 59(20):5250-4. . View in PubMed

Effects of TGF-beta on the immune system: implications for cancer immunotherapy Leukemia. 1999 Aug; 13(8):1188-99. . View in PubMed

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial Eur J Cancer. 1999 Jun; 35(6):946-52. . View in PubMed

Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response J Cell Biochem. 1999 May 01; 73(2):145-52. . View in PubMed

Modulation of the immune response and tumor growth by activated Ras Leukemia. 1999 Apr; 13(4):502-13. . View in PubMed

Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles Biol Chem. 1999 Mar; 380(3):335-40. . View in PubMed

Papillomavirus virus-like particles as anticancer vaccines Curr Opin Mol Ther. 1999 Feb; 1(1):82-8. . View in PubMed

Differential binding of viral peptides to HLA-A2 allelesImplications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur J Immunol. 1999 04; 29(4):1292-303. . View in PubMed

Differences in the effectiveness of delivery of B- and CTL-epitopes incorporated into the hepatitis B core antigen (HBcAg) c/e1-region Arch Virol. 1999; 144(7):1323-43. . View in PubMed

Active immunization against cancer cells: impediments and advances Semin Oncol. 1998 Dec; 25(6):697-706. . View in PubMed

Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope J Immunother. 1998 Nov; 21(6):399-408. . View in PubMed

L1-specific protection from tumor challenge elicited by HPV16 virus-like particles Virology. 1998 Oct 25; 250(2):371-6. . View in PubMed

Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC Cancer Res. 1998 Jul 15; 58(14):3094-100. . View in PubMed

PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired J Immunother. 1998 Jul; 21(4):317-22. . View in PubMed

Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells J Immunol. 1998 May 01; 160(9):4449-56. . View in PubMed

The biological activities of simian virus 40 large-T antigen and its possible oncogenic effects in humans Monaldi Arch Chest Dis. 1998 Apr; 53(2):193-7. . View in PubMed

The detection of simian virus 40 in human tumors by polymerase chain reaction Monaldi Arch Chest Dis. 1998 Apr; 53(2):202-10. . View in PubMed

Cellular immunity and immunotherapy against deoxyribonucleic acid virus-induced tumors Monaldi Arch Chest Dis. 1998 Apr; 53(2):211-8. . View in PubMed

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model Proc Natl Acad Sci U S A. 1998 Feb 17; 95(4):1800-5. . View in PubMed

Identification of peptides for immunotherapy of cancerIt is worth the effort. Crit Rev Immunol. 1998; 18(1-2):7-27. . View in PubMed

Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas Dev Biol Stand. 1998; 94:33-40. . View in PubMed

Targeting of cytotoxic T cells against leukemic B cells by bispecific antibody (aCD3 x aCD19) does not distract the T cell from its primary target J Immunol. 1997 Dec 01; 159(11):5545-9. . View in PubMed

Activation or frustration of anti-tumor responses by T-cell-based immune modulation Semin Immunol. 1997 Oct; 9(5):323-7. . View in PubMed

HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS J Immunol. 1997 Oct 01; 159(7):3648-54. . View in PubMed

Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product Int J Cancer. 1997 Sep 26; 73(1):125-30. . View in PubMed

Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes J Exp Med. 1997 Aug 29; 186(5):695-704. . View in PubMed

Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes Cancer Lett. 1997 Jun 03; 116(1):93-101. . View in PubMed

The current status of therapeutic HPV vaccine Ann Med. 1996 Dec; 28(6):471-7. . View in PubMed

Peptide specificity of alloreactive CD4 positive T lymphocytes directed against a major histocompatibility complex class I disparity Transplantation. 1996 Nov 27; 62(10):1485-91. . View in PubMed

Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity Immunotechnology. 1996 Nov; 2(4):241-51. . View in PubMed

Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer Clin Cancer Res. 1996 Nov; 2(11):1825-8. . View in PubMed

Peptide-based cancer vaccines Curr Opin Immunol. 1996 Oct; 8(5):651-7. . View in PubMed

Protective antitumor immunity induced by immunization with completely allogeneic tumor cells Cancer Res. 1996 Aug 15; 56(16):3782-7. . View in PubMed

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction Proc Natl Acad Sci U S A. 1996 Jul 23; 93(15):7855-60. . View in PubMed

Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts Int J Cancer. 1996 May 29; 66(5):686-91. . View in PubMed

Enhanced tumor outgrowth after peptide vaccinationFunctional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol. 1996 May 15; 156(10):3911-8. . View in PubMed

Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability J Immunol. 1996 May 01; 156(9):3308-14. . View in PubMed

Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope Cancer Res. 1996 Feb 01; 56(3):582-8. . View in PubMed

An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cellsIdentification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol. 1995 Dec; 44(4):189-98. . View in PubMed

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity Nat Med. 1995 Dec; 1(12):1297-302. . View in PubMed

Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors Eur J Immunol. 1995 Sep; 25(9):2638-42. . View in PubMed

The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes J Immunother Emphasis Tumor Immunol. 1995 Aug; 18(2):77-85. . View in PubMed

Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor J Immunother Emphasis Tumor Immunol. 1995 Aug; 18(2):86-94. . View in PubMed

Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape Biochem Soc Trans. 1995 Aug; 23(3):692-6. . View in PubMed

Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization Immunol Lett. 1995 Jul-Aug; 47(1-2):1-8. . View in PubMed

Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells J Exp Med. 1995 Jul 01; 182(1):163-74. . View in PubMed

Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2 Cancer Res. 1995 Jun 15; 55(12):2627-34. . View in PubMed

Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides J Immunol. 1995 Jun 01; 154(11):5934-43. . View in PubMed

T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes Immunol Rev. 1995 Jun; 145:167-77. . View in PubMed

MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells J Immunol. 1995 Jun 01; 154(11):5715-24. . View in PubMed

Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201 Int J Cancer. 1995 May 04; 61(3):389-96. . View in PubMed

A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs Hum Immunol. 1995 May; 43(1):13-8. . View in PubMed

Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay Hum Immunol. 1995 May; 43(1):1-12. . View in PubMed

CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells J Immunol. 1995 Apr 15; 154(8):3991-8. . View in PubMed

An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene J Immunol. 1995 Apr 01; 154(7):3396-405. . View in PubMed

Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences J Immunol. 1995 Feb 01; 154(3):1273-9. . View in PubMed

Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase AIDS. 1995 Feb; 9(2):121-7. . View in PubMed

Class I MHC-peptide interactions: structural requirements and functional implications Cancer Surv. 1995; 22:37-49. . View in PubMed

Functional and ultrastructural aspects of antigen processing by dendritic cells Adv Exp Med Biol. 1995; 378:227-31. . View in PubMed

The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes J Immunol. 1994 Dec 15; 153(12):5586-92. . View in PubMed

Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity Mol Immunol. 1994 Dec; 31(18):1391-401. . View in PubMed

Identification of an H-2 Kb-presented Moloney murine leukemia virus cytotoxic T-lymphocyte epitope that displays enhanced recognition in H-2 Db mutant bm13 mice J Virol. 1994 Sep; 68(9):6038-46. . View in PubMed

Tumor rejection antigens and tumor specific cytotoxic T lymphocytes Behring Inst Mitt. 1994 Jul; (94):72-86. . View in PubMed

p53, a potential target for tumor-directed T cells Immunol Lett. 1994 May; 40(2):171-8. . View in PubMed

Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins J Immunol. 1994 Apr 15; 152(8):3904-12. . View in PubMed

Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity J Immunother Emphasis Tumor Immunol. 1994 Feb; 15(2):119-28. . View in PubMed

Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides Ciba Found Symp. 1994; 187:97-104; discussion 104-12. . View in PubMed

Differential effect of transporter Tap 2 gene introduction into RMA-S cells on viral antigen processing Eur J Immunol. 1993 Dec; 23(12):3082-8. . View in PubMed

Potential immunogenicity of oncogene and tumor suppressor gene products Curr Opin Immunol. 1993 Oct; 5(5):709-13. . View in PubMed

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53 Eur J Immunol. 1993 Sep; 23(9):2072-7. . View in PubMed

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells Eur J Immunol. 1993 Sep; 23(9):2242-9. . View in PubMed

Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides J Immunother Emphasis Tumor Immunol. 1993 Aug; 14(2):121-6. . View in PubMed

Human leukocyte antigen-A21 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother Emphasis Tumor Immunol. 1993 Aug; 14(2):115-20. . View in PubMed

In vivo detection of fluorescent tumor-specific cytotoxic T cell clones J Immunol Methods. 1993 Jul 06; 163(1):23-32. . View in PubMed

Murine cytomegalovirus interacts with major histocompatibility complex class I molecules to establish cellular infection J Virol. 1993 Jul; 67(7):4182-9. . View in PubMed

Identification of peptide sequences that potentially trigger HLA-A21-restricted cytotoxic T lymphocytes. Eur J Immunol. 1993 Jun; 23(6):1215-9. . View in PubMed

Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination Eur J Immunol. 1993 May; 23(5):1189-92. . View in PubMed

The MHC expression of dendritic cells from mouse spleen isolated by centrifugal elutriation is upregulated during short term culture Adv Exp Med Biol. 1993; 329:185-9. . View in PubMed

Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses Eur J Immunol. 1992 Nov; 22(11):3013-20. . View in PubMed

A rapid isolation procedure for dendritic cells from mouse spleen by centrifugal elutriation J Immunol Methods. 1992 Oct 19; 155(1):101-11. . View in PubMed

Cytotoxic T lymphocytes against the antigen-processing-defective RMA-S tumor cell line Eur J Immunol. 1992 Jun; 22(6):1639-42. . View in PubMed

Lessons from T cell responses to virus induced tumours for cancer eradication in general Cancer Surv. 1992; 13:81-99. . View in PubMed

Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses Eur J Immunol. 1991 Dec; 21(12):2963-70. . View in PubMed

Pretransplantation blood transfusion revisited N Engl J Med. 1991 Oct 24; 325(17):1210-3. . View in PubMed

In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes Immunol Lett. 1991 Oct; 30(2):229-32. . View in PubMed

Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms Semin Cancer Biol. 1991 Oct; 2(5):347-54. . View in PubMed

T-cell immunotherapy of cancer Res Immunol. 1991 Jun-Aug; 142(5-6):425-9. . View in PubMed

Peptide selection by MHC class I molecules Nature. 1991 Apr 25; 350(6320):703-6. . View in PubMed

Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide Proc Natl Acad Sci U S A. 1991 Mar 15; 88(6):2283-7. . View in PubMed

Mechanisms of transplantation tolerance: do anti-idiotypic antibodies play a role? Transplant Proc. 1991 Feb; 23(1 Pt 1):155-6.. View in PubMed

Fine peptide specificity of cytotoxic T lymphocytes directed against adenovirus-induced tumours and peptide-MHC binding Int J Cancer Suppl. 1991; 6:90-4. . View in PubMed

Different requirements for the regulation of transplantation tolerance induction for allogeneic versus xenogeneic major histocompatibility complex antigens Hum Immunol. 1990 Nov; 29(3):220-8. . View in PubMed

Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells J Immunol. 1990 Oct 01; 145(7):2254-9. . View in PubMed

Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro Cell. 1990 Aug 10; 62(3):563-7. . View in PubMed

Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells EMBO J. 1990 Aug; 9(8):2621-9. . View in PubMed

Efficacy of cytotoxic T lymphocytes against virus-induced tumors Cancer Cells. 1990 Apr; 2(4):116-20. . View in PubMed

Induction of transplantation tolerance by intravenous injection of allogeneic lymphocytes across an H-2 class II mismatchDifferent mechanisms operate in tolerization across an H-2 class I vs. H-2 class II disparity. Eur J Immunol. 1990 Feb; 20(2):441-4. . View in PubMed

Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes Cell. 1989 Nov 17; 59(4):603-14. . View in PubMed

Allograft tolerance induction in adult mice associated with functional deletion of specific CTL precursors Transplantation. 1989 Nov; 48(5):844-7. . View in PubMed

Lack of correlation between levels of MHC class I antigen and susceptibility to lysis of small cellular lung carcinoma (SCLC) by natural killer cells J Immunol. 1989 Jun 01; 142(11):4113-7. . View in PubMed

Transfusion-induced skin allograft enhancement across an H-2 class-I mismatch is caused by a clonal deletion of donor-specific cytotoxic T-lymphocyte precursors within the allograft Transplant Proc. 1989 Feb; 21(1 Pt 1):1169-70. . View in PubMed

Immunosurveillance of virus-induced tumors Cold Spring Harb Symp Quant Biol. 1989; 54 Pt 1:597-603. . View in PubMed

Mechanism of skin allograft enhancement across an H-2 class I mutant differenceEvidence for involvement of veto cells. Eur J Immunol. 1988 Dec; 18(12):2105-8. . View in PubMed

Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells J Immunol. 1988 May 01; 140(9):3186-93. . View in PubMed

Dendritic cells and antigen presentation in the regulation of cytotoxic T lymphocyte responses against viruses and transplantation antigens Ann N Y Acad Sci. 1988; 532:280-91. . View in PubMed

Thymic immune response gene function in radiation chimeras reconstituted with purified hemopoietic stem cells Eur J Immunol. 1987 Apr; 17(4):471-5. . View in PubMed

Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infectionProtection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations. J Exp Med. 1986 Sep 01; 164(3):723-38. . View in PubMed

Alternative splicing in the mouse H-2Kd gene is not necessary for the classical Kd antigen function Immunogenetics. 1986; 24(4):267-74. . View in PubMed

Abolition of specific immune response defect by immunization with dendritic cells Nature. 1985 Nov 7-13; 318(6041):59-62. . View in PubMed

Thymus dictates major histocompatibility complex (MHC) specificity and immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC-restricted T cells J Exp Med. 1984 Dec 01; 160(6):1752-66. . View in PubMed

Specificity and regulation of cytotoxic T-lymphocyte responses analyzed with H-2 mutants Transplant Proc. 1983 Dec; 15(4):2086-9. . View in PubMed

Regulation of the cytotoxic T lymphocyte response against Sendai virus analyzed with H-2 mutants J Immunol. 1983 Mar; 130(3):1090-6. . View in PubMed

The peroxidation of thiocyanate catalysed by myeloperoxidase and lactoperoxidase Biochim Biophys Acta. 1982 Dec 20; 709(2):212-9. . View in PubMed